Skip to content
value.today

Deciphera Pharmaceuticals, LLC

🇺🇸 Waltham, Massachusetts, USAPharmaceuticalsFounded 2015
Total raised
$143 M
2 rounds on record
Latest round
$52 M
May 2017
First round on record
Sep 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Deciphera Pharmaceuticals, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2017$52 MNo. 2$50 to $250 million

Deciphera Pharmaceuticals, LLC: Raise no. 2, May 2017

Investors in this round

7 investors had bought by the notice of Jun 5, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Deciphera Pharmaceuticals, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$52 M of $52 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Christopher J. Morl · Executive Officer
  • Daniel L. Flynn, Ph.D. · Executive Officer
  • Michael D. Taylor, Ph.D. · Executive Officer, Director
  • Oliver L. Rosen, M.D. · Executive Officer
  • Thomas L. Kelly · Executive Officer
  • Dennis A. Walsh · Director
  • Edward J. Benz, Jr. · Director
  • James A. Bristol, Ph.D. · Director
  • John A. Martin · Director
  • Liam A. Ratcliffe, M.D., Ph.D. · Director
  • Michael A. Ross · Director
  • Patricia L. Allen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael D. Taylor, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Jun 5, 2017. Read the notice at the SEC.

equitySEC
Sep 2015$91 MNo. 1$50 to $250 million

Deciphera Pharmaceuticals, LLC: Raise no. 1, Sep 2015

Investors in this round

5 investors had bought by the notice of Jul 14, 2016: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Deciphera Pharmaceuticals, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$91 M of $91 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Daniel F. Flynn, Ph.D. · Executive Officer
  • Michael Taylor · Executive Officer, Director
  • Oliver F. Rosen, M.D. · Executive Officer
  • Thomas F. Kelly · Executive Officer
  • Dennis A. Walsh · Director
  • James A. Bristol, Ph.D. · Director
  • John A. Martin · Director
  • Liam A. Ratcliffe, M.D., Ph.D. · Director
  • Michael A. Ross · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael D. Taylor, Ph.D., President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Jul 14, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Deciphera Pharmaceuticals, LLC chose not to state its revenue in its newest notice of a funding round (Jun 2017).

    SEC Form D · Jun 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2017

That is all the official record says: Deciphera Pharmaceuticals, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Deciphera Pharmaceuticals, LLC
InvestorKindAmountRoundRoleSource
Brightstar Associates LLCOthernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Leaf Biopharma Opportunities I, L.P.Fund or asset managernot statednot statedHeld Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Leaf BPO Associates I, L.P.Fund or asset managernot statednot statedHeld Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Leaf Venture Associates III, L.P.Venture capitalnot statednot statedHeld Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Leaf Venture Management III, L.L.C.Venture capitalnot statednot statedHeld Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
New Leaf Ventures III, L.P.Venture capitalnot statednot statedHeld Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Deciphera Pharmaceuticals, LLC
NameRoleNamed in
Christopher J. MorlExecutive officerJun 2017
Daniel L. Flynn, Ph.D.Executive officerJun 2017
Michael D. Taylor, Ph.D.Executive officerJun 2017
Oliver L. Rosen, M.D.Executive officerJun 2017
Thomas L. KellyExecutive officerJun 2017
Daniel F. Flynn, Ph.D.Executive officerJul 2016
Michael TaylorExecutive officerJul 2016
Oliver F. Rosen, M.D.Executive officerJul 2016
Thomas F. KellyExecutive officerJul 2016
Dennis A. WalshDirectorJun 2017
Edward J. Benz, Jr.DirectorJun 2017
James A. Bristol, Ph.D.DirectorJun 2017
John A. MartinDirectorJun 2017
Liam A. Ratcliffe, M.D., Ph.D.DirectorJun 2017
Michael A. RossDirectorJun 2017
Michael D. Taylor, Ph.D.DirectorJun 2017
Patricia L. AllenDirectorJun 2017
Michael TaylorDirectorJul 2016